Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTO)
NASDAQ:APTO
APTO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.39 - $51.60
Previous Close$0.22
Volume837.49K
Average Volume (3M)267.01K
Market Cap
$7.17M
Enterprise Value$13.56M
Total Cash (Recent Filing)$15.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
May 12, 2025EPS Estimate
-2.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-91.40
Shares Outstanding2,143,366
10 Day Avg. Volume22,519
30 Day Avg. Volume267,013
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$9.25Price Target Upside178.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Aptose Biosciences News
PremiumCompany Announcements
Aptose Biosciences Advances AML Therapy and Strengthens Financial Position
PremiumCompany Announcements
Aptose Biosciences Regains Nasdaq Bid Price Compliance---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement designed to provide necessary additional funding and accelerate clinical development.
Clinical TrialsThe TUSCANY trial could position TUS as a promising combination therapy for larger AML populations, avoiding the toxicities observed with other agents.
Safety ProfileThe absence of conspicuous safety signals is an indication of TUS's and the combo therapy's favorable safety and tolerability.
Bears Say
Treatment EfficacyThe doublet therapy shows effectiveness among patients with adverse mutations and prior treatment failures.
---
Ownership Overview
33.30% Insiders
<0.01% Mutual Funds
6.36% Other Institutional Investors
66.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
APTO FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was $2.39 and its highest was $51.60 in the past 12 months.
What is Aptose Biosciences’s market cap?
Aptose Biosciences’s market cap is $7.17M.
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is May 12, 2025 which is in 42 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on Mar 28, 2025. The company reported $9.52 earnings per share for the quarter, beating the consensus estimate of -$6.775 by $16.295.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -2.58.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 2,143,366 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of $9.52 in its last earnings report, beating expectations of -$6.775. Following the earnings report the stock price went down -10.27%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Among the largest hedge funds holding Aptose Biosciences’s share is Carlson Capital LP. It holds Aptose Biosciences’s shares valued at 0.
---
Company Description
Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
---
APTO Stock 12 Month Forecast
Average Price Target
$9.25
▲(178.61% Upside)
Technical Analysis
Best Analysts Covering APTO
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-61.00%
reiterated a buy rating 11 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -61.00% per trade.
---